Stockreport

Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Lineage Cell Therapeutics, Inc.  (LCTX) 
PDF Positive RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025Entered Collaboration with William Demant Invest to D [Read more]